Advances in the diagnosis and surveillance of Barrett's esophagus (with videos)

The ASGE Technology Committee

Research output: Contribution to journalArticle

Abstract

Background and Aims: Most patients diagnosed with esophageal adenocarcinoma do not carry a known diagnosis of Barrett's esophagus (BE), suggesting that an improved approach to screening may potentially be of benefit. The use of dysplasia as a biomarker and random biopsy protocols for its detection has limitations. In addition, detecting and appropriately classifying dysplasia in patients with known BE can be difficult. Methods: This document reviews several technologies with a recently established or potential role in the diagnosis and/or surveillance of BE as well as risk stratification for progression to esophageal adenocarcinoma. Results: Two technologies were reviewed for imaging or tissue sampling: (1)wide-area transepithelial sampling and (2)volumetric laser endomicroscopy. Four technologies were reviewed for molecular and biomarker technologies for diagnosis and risk stratification: (1)Cytosponge, (2)mutational load, (3)fluorescence in situ hybridization, and (4)immunohistochemistry. Conclusion: Several technologies discussed in this document may improve dysplasia detection in BE in a wide-field manner. Moreover, the addition of different biomarkers may aid in enhanced risk stratification to optimize approaches to surveillance or treatment for patients with BE.

Original languageEnglish (US)
JournalGastrointestinal endoscopy
DOIs
StatePublished - Jan 1 2019

Fingerprint

Barrett Esophagus
Technology
Biomarkers
Adenocarcinoma
Fluorescence In Situ Hybridization
Lasers
Immunohistochemistry
Biopsy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Cite this

Advances in the diagnosis and surveillance of Barrett's esophagus (with videos). / The ASGE Technology Committee.

In: Gastrointestinal endoscopy, 01.01.2019.

Research output: Contribution to journalArticle

@article{5c00f9a8fd17465bb4f3fb07e1084343,
title = "Advances in the diagnosis and surveillance of Barrett's esophagus (with videos)",
abstract = "Background and Aims: Most patients diagnosed with esophageal adenocarcinoma do not carry a known diagnosis of Barrett's esophagus (BE), suggesting that an improved approach to screening may potentially be of benefit. The use of dysplasia as a biomarker and random biopsy protocols for its detection has limitations. In addition, detecting and appropriately classifying dysplasia in patients with known BE can be difficult. Methods: This document reviews several technologies with a recently established or potential role in the diagnosis and/or surveillance of BE as well as risk stratification for progression to esophageal adenocarcinoma. Results: Two technologies were reviewed for imaging or tissue sampling: (1)wide-area transepithelial sampling and (2)volumetric laser endomicroscopy. Four technologies were reviewed for molecular and biomarker technologies for diagnosis and risk stratification: (1)Cytosponge, (2)mutational load, (3)fluorescence in situ hybridization, and (4)immunohistochemistry. Conclusion: Several technologies discussed in this document may improve dysplasia detection in BE in a wide-field manner. Moreover, the addition of different biomarkers may aid in enhanced risk stratification to optimize approaches to surveillance or treatment for patients with BE.",
author = "{The ASGE Technology Committee} and Trindade, {Arvind J.} and Udayakumar Navaneethan and Aslanian, {Harry R.} and Bhutani, {Manoop S.} and Kumar Krishnan and Lichtenstein, {David R.} and Joshua Melson and Rahul Pannala and Parsi, {Mansour A.} and Schulman, {Allison R.} and Amrita Sethi and Guru Trikudanathan and Watson, {Rabindra R.} and Maple, {John T.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.gie.2019.05.004",
language = "English (US)",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Advances in the diagnosis and surveillance of Barrett's esophagus (with videos)

AU - The ASGE Technology Committee

AU - Trindade, Arvind J.

AU - Navaneethan, Udayakumar

AU - Aslanian, Harry R.

AU - Bhutani, Manoop S.

AU - Krishnan, Kumar

AU - Lichtenstein, David R.

AU - Melson, Joshua

AU - Pannala, Rahul

AU - Parsi, Mansour A.

AU - Schulman, Allison R.

AU - Sethi, Amrita

AU - Trikudanathan, Guru

AU - Watson, Rabindra R.

AU - Maple, John T.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and Aims: Most patients diagnosed with esophageal adenocarcinoma do not carry a known diagnosis of Barrett's esophagus (BE), suggesting that an improved approach to screening may potentially be of benefit. The use of dysplasia as a biomarker and random biopsy protocols for its detection has limitations. In addition, detecting and appropriately classifying dysplasia in patients with known BE can be difficult. Methods: This document reviews several technologies with a recently established or potential role in the diagnosis and/or surveillance of BE as well as risk stratification for progression to esophageal adenocarcinoma. Results: Two technologies were reviewed for imaging or tissue sampling: (1)wide-area transepithelial sampling and (2)volumetric laser endomicroscopy. Four technologies were reviewed for molecular and biomarker technologies for diagnosis and risk stratification: (1)Cytosponge, (2)mutational load, (3)fluorescence in situ hybridization, and (4)immunohistochemistry. Conclusion: Several technologies discussed in this document may improve dysplasia detection in BE in a wide-field manner. Moreover, the addition of different biomarkers may aid in enhanced risk stratification to optimize approaches to surveillance or treatment for patients with BE.

AB - Background and Aims: Most patients diagnosed with esophageal adenocarcinoma do not carry a known diagnosis of Barrett's esophagus (BE), suggesting that an improved approach to screening may potentially be of benefit. The use of dysplasia as a biomarker and random biopsy protocols for its detection has limitations. In addition, detecting and appropriately classifying dysplasia in patients with known BE can be difficult. Methods: This document reviews several technologies with a recently established or potential role in the diagnosis and/or surveillance of BE as well as risk stratification for progression to esophageal adenocarcinoma. Results: Two technologies were reviewed for imaging or tissue sampling: (1)wide-area transepithelial sampling and (2)volumetric laser endomicroscopy. Four technologies were reviewed for molecular and biomarker technologies for diagnosis and risk stratification: (1)Cytosponge, (2)mutational load, (3)fluorescence in situ hybridization, and (4)immunohistochemistry. Conclusion: Several technologies discussed in this document may improve dysplasia detection in BE in a wide-field manner. Moreover, the addition of different biomarkers may aid in enhanced risk stratification to optimize approaches to surveillance or treatment for patients with BE.

UR - http://www.scopus.com/inward/record.url?scp=85065784588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065784588&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2019.05.004

DO - 10.1016/j.gie.2019.05.004

M3 - Article

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

ER -